WIP Antibody (C-1): sc-390099

WIP Antibody (C-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects WIP protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-WIP antibody (C-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The Wiskott-Aldrich syndrome protein (WASP) is crucial for immune function, and mutations in WASP can lead to immunodeficiency due to improper T cell and B cell activation. The 503 amino acid WAS-interacting protein (WIP) plays a significant role in this process, containing several domains that facilitate actin-binding and src homology interactions. Notably, the first 100 amino acids of WASP interact with amino acids 377-503 of WIP, and most pathogenic mutations associated with Wiskott-Aldrich syndrome occur within this region. The gene encoding human WIP is located on chromosome 2q31.1, and studies have shown that WIP overexpression in the human B cell line BJAB enhances F-actin content and promotes cerebriform projection formation. Additionally, WIP and Vav work together to regulate NF-AT/AP-1 gene transcription, with the WIP-WASP complex being essential for NF-AT/AP-1 activation, which is vital for proper T cell function. Disruption of the WIP-WASP complex may contribute to the immunodeficient phenotype observed in Wiskott-Aldrich syndrome, highlighting WIP′s importance in maintaining immune system integrity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

WIP Antibody (C-1) References:

1. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein.  |  Stewart, DM., et al. 1999. J Immunol. 162: 5019-24. PMID: 10202051
2. Cutting edge: WIP, a binding partner for Wiskott-Aldrich syndrome protein, cooperates with Vav in the regulation of T cell activation.  |  Savoy, DN., et al. 2000. J Immunol. 164: 2866-70. PMID: 10706671
3. WIP remodeling actin behind the scenes: how WIP reshapes immune and other functions.  |  Noy, E., et al. 2012. Int J Mol Sci. 13: 7629-7647. PMID: 22837718
4. WIP is necessary for matrix invasion by breast cancer cells.  |  García, E., et al. 2014. Eur J Cell Biol. 93: 413-23. PMID: 25169059
5. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.  |  Escoll, M., et al. 2017. Oncogene. 36: 3515-3527. PMID: 28166194
6. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.  |  Yu, W., et al. 2020. Cell Death Dis. 11: 506. PMID: 32632098
7. Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition.  |  Li, J., et al. 2022. Nat Cancer. 3: 453-470. PMID: 35484420
8. CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy.  |  Dong, Y., et al. 2023. J Exp Clin Cancer Res. 42: 68. PMID: 36935496
9. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity.  |  Cooper, MD., et al. 1968. Am J Med. 44: 499-513. PMID: 4171085
10. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome.  |  Derry, JM., et al. 1994. Cell. 78: 635-44. PMID: 8069912
11. WASPbase: a database of WAS- and XLT-causing mutations.  |  Schwarz, K. 1996. Immunol Today. 17: 496-502. PMID: 8961624
12. WIP, a protein associated with wiskott-aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells.  |  Ramesh, N., et al. 1997. Proc Natl Acad Sci U S A. 94: 14671-6. PMID: 9405671

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-WIP Antibody (C-1) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-WIP Antibody (C-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

WIP Antibody (C-1) Specifications

Alternate Product Name: WIP

Product Clone Name: C-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 91-129

Epitope Target: WIP

Epitope Species: human

Product Reactivity/Detection: WIP

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for WIP Antibody (C-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin